Novel therapies, often with expensive price tags and finite patient populations, require strategic new positioning if they are to have maximum positive impact.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh